@article{Wang2025, 
author = {Kaifang Wang and Yue Zhang and Baowen Dong and Kailu Li and Saiying Wang and Tao Peng and Jinyuan Meng and Mengmeng Chang and Lu Huang and Li Sun and Shuyuan Wang and Zhifei Fu and Le Yang and Hao Guo and Dayun Feng and Changjun Gao},
title = {Bioinspired vasculogenic-nanovesicle: A dual-targeted therapeutic platform for ischemic stroke through vascular remodeling and anti-inflammation},
year = {2025},
journal = {Nano Research},
volume = {18},
number = {9},
pages = {94907738},
keywords = {ischemic stroke, cerebrovascular recanalization, Arg1+ microglia, vascular neogenesis, interleukin-4-functionalized vasculogenic-nanovesicle (IL4@SDNV)},
url = {https://www.sciopen.com/article/10.26599/NR.2025.94907738},
doi = {10.26599/NR.2025.94907738},
abstract = {Therapeutic strategies for cerebral ischemic stroke face critical challenges in mitigating secondary cerebrovascular injury following recanalization. In this study, we engineered interleukin-4-functionalized vasculogenic-nanovesicles (IL4@SDNVs) that exhibit tripartite therapeutic efficacy: preserving blood-brain barrier integrity, suppressing neuroinflammatory cascades, specifically microglial pro-inflammatory polarization and peripheral immune cell infiltration, and inducing EMCN+/CD31+ vascular neogenesis and achieving 144.1% increase in cerebral blood perfusion within the ischemic hemisphere in a mouse middle cerebral artery occlusion (MCAO) model. Mechanistically, post-recanalization administration of IL4@SDNV selectively promoted arginase-1+ (Arg1+) microglial polarization in the ischemic penumbra via the IL4-STAT6 signaling pathway, thereby exerting neuroprotection and cerebrovascular remodeling. Collectively, our findings demonstrate that IL4@SDNV as a promising adjuvant therapy for ischemic stroke post-recanalization through addressing cerebrovascular pathology and neuroinflammation simultaneously, thus highlighting its translational potential for clinical application.}
}